RxSight reports preliminary Q4/FY2024 rev ~$40.2M/$139.9M, +41%/+57% YoY; guides 2025 rev $185-197M

RxSight, Inc.

2024-FY EPS reported -$0.71 revenue$139,927,000

Q4 2024 revenue ~$40.2M (+41% YoY); FY2024 ~$139.9M (+57% YoY).
LAL procedure volume Q4 29,069 (+61% YoY); FY 98,055 (+79% YoY).
LDD installed base 971 as of Dec 31 (+46% YoY); cash & investments $237.2M.
2025 revenue guidance $185M-$197M (32-41% growth); gross margin 71-73%.
Preliminary results subject to audit; audited FY2024 & unaudited Q4 due Feb 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.